Healthcare / Medical Instruments & SuppliesTokyo
$2090.00
-5.00 (-0.24%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.1B · quality 74.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$50.6B
P/E
13.5x
↓EV/EBITDA
8.1x
↓ROE
20.8%
↑Gross Margin
78.7%
↑Debt/Equity
0.86
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+20.2%
FCF CAGR
+21.1%
FCF margin
24.9%
FCF / Net income
1.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $18.64B · net income $3.78B · FCF $4.64B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $18.64B | $18.64B | $16.67B | $13.53B | $10.72B |
| Net Income | $3.78B | $3.78B | $3.99B | $2.22B | $292.0M |
| EBITDA | $7.87B | $7.87B | $7.01B | $5.18B | $3.63B |
| EPS | 154.41 | 154.41 | 163.09 | 108.03 | 25.04 |
| Gross Margin | 78.7% | 78.7% | 78.9% | 77.5% | 76.6% |
| Operating Margin | 32.0% | 32.0% | 32.0% | 27.4% | 20.8% |
| Net Margin | 20.3% | 20.3% | 24.0% | 16.4% | 2.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.86 | 0.86 | 1.01 | 1.24 | 3.66 |
| Current Ratio | 0.44 | 0.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $4.64B | $4.64B | $3.08B | $2.67B | $2.62B |
| Returns | |||||
| ROE | 20.8% | 20.8% | 24.3% | 16.7% | 6.2% |
| Valuation | |||||
| P/E | 13.53 | 13.53 | 14.07 | 13.24 | — |
| EV/EBITDA | 8.10 | 8.10 | 9.83 | 7.98 | — |
| P/B | 2.82 | 2.82 | 3.42 | 2.21 | — |
| Growth & Yield | |||||
| Revenue Growth | 11.8% | 11.8% | 23.2% | 26.2% | — |
| EPS Growth | -5.3% | -5.3% | 51.0% | 331.4% | — |
| Dividend Yield | 4.1% | 4.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
6.3%
EPS terminal req.
$185.45
Spread vs growth
-11.6%
5Y implied EPS CAGR
7.8%
EPS terminal req.
$224.40
Spread vs growth
-13.1%
10Y implied EPS CAGR
8.9%
EPS terminal req.
$361.39
Spread vs growth
-14.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.7%
Start / end P/E
14.0x → 13.5x
EPS bridge
163.09 → 154.41
Residual
+0.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.